Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep:188:198-204.e1.
doi: 10.1016/j.jpeds.2017.05.049. Epub 2017 Jun 16.

Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe

Rgia A Othman  1 , Semone B Myrie  2 , David Mymin  3 , Jean-Baptiste Roullet  4 , Andrea E DeBarber  5 , Robert D Steiner  6 , Peter J H Jones  1
Affiliations
Clinical Trial

Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe

Rgia A Othman et al. J Pediatr. 2017 Sep.

Abstract

Objectives: To assess the association between biomarkers of thyroid status and 5α-stanols in patients with sitosterolemia treated with ezetimibe (EZE).

Study design: Eight patients with sitosterolemia (16-56 years of age) were studied during 14 weeks off EZE therapy and 14 weeks on EZE (10 mg/day). Serum thyroid biomarkers (free triiodothyronine [FT3], free thyroxine [FT4], FT3/FT4 ratio, thyroid-stimulating hormone), 5α-stanols (sitostanol and cholestanol), and cholestanol precursors (total cholesterol and its synthesis marker lathosterol, and 7α-hydroxy-4-cholesten-3-one cholestenol) were measured at baseline and during the 14 weeks off EZE and on EZE.

Results: EZE increased FT3/FT4 (10% ± 4%; P = .02). EZE reduced plasma and red blood cells sitostanol (-38% ± 6% and -20% ± 4%; all P < .05) and cholestanol (-18% ± 6% and -13% ± 3%; all P < .05). The change in plasma cholestanol level on EZE inversely correlated with the change in FT3/FT4 (r = -0.86; P = .01). EZE lowered total cholesterol (P < .0001) and did not affect 7α-hydroxy-4-cholesten-3-one cholestanol. EZE increased (P < .0001) lathosterol initially, but the level was not sustained, resulting in similar levels at week 14 off EZE and on EZE.

Conclusion: In patients with STSL, 5α-stanols levels might be associated with thyroid function. EZE reduces circulating 5α-stanols while increasing FT3/FT4, implying increased conversion of T4 to T3, thus possibly improving thyroid hormone status.

Trial registration: ClinicalTrials.govNCT01584206.

Keywords: 7α-hydroxy-4-cholesten-3-one; cholestanol; lathosterol; phytosterolemia; sitostanol; total cholesterol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A, Serum FT3, B, FT4, C, FT3/FT4 and D, TSH levels in patients with STSL (n = 8) at 8 and 14 weeks off EZE (OFF EZE) and on EZE (ON EZE). Data are mean ± SEM. *P < .05; Wk, week.
Figure 2
Figure 2
A and B, Plasma and RBC sitostanol, C and D, plasma and RBC cholestanol, and E and F, plasma and RBC TC levels in patients with STSL (n = 8) throughout 14 weeks off EZE (OFF EZE) and on EZE (ON EZE). Data are mean ± SEM. *P < .05, **P < .01, ***P <.0001 vs OFF EZE. † P < .05 vs baseline; Wk, week.
Figure 3
Figure 3
A and B, Plasma and RBC lathosterol levels and C, serum 7α-H-C4 in patients with STSL (n = 8) throughout 14 weeks off EZE (OFF EZE) and on EZE (ON EZE). Data are mean ± SEM. *P < .05, **P < .01, ***P <.0001 vs OFF EZE. † P < .05 vs baseline; Wk, week.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Othman RA, Myrie SB, Jones PJ. Non-cholesterol sterols and cholesterol metabolism in sitosterolemia. Atherosclerosis. 2013;231:291–9. - PubMed
    1. Wang C, Lin HJ, Chan TK, Salen G, Chan WC, Tse TF. A unique patient with coexisting cerebrotendinous xanthomatosis and beta-sitosterolemia. The American journal of medicine. 1981;71:313–9. - PubMed
    1. Mushtaq T, Wales JK, Wright NP. Adrenal insufficiency in phytosterolaemia. European journal of endocrinology / European Federation of Endocrine Societies. 2007;157(Suppl 1):S61–5. - PubMed
    1. Idouji K, Kuriyama M, Fujiyama J, Osame M, Hoshita T. [Hypothyroidism with increased serum levels of cholestanol and bile alcohol--analogous symptoms to cerebrotendinous xanthomatosis] Rinsho shinkeigaku = Clinical neurology. 1991;31:402–6. - PubMed
    1. Bouwes Bavinck JN, Vermeer BJ, Gevers Leuven JA, Koopman BJ, Wolthers BG. Capillary gas chromatography of urine samples in diagnosing cerebrotendinous xanthomatosis. Archives of dermatology. 1986;122:1269–72. - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data